Tag: tofacitinib

1. In a posthoc analysis of 2, phase 3 randomized controlled trials of over 1000 patients with moderate-to-severe plaque psoriasis, tofacitinib (an oral Janus kinase inhibitor) treatment demonstrated significantly improved clinical nail psoriasis severity scores at 16 weeks compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Psoriasis is a...
1. At 6 months, patients receiving tofacitinib monotherapy had reduced structural joint damage compared to methotrexate monotherapy.  2. Patients treated with tofacitinib had increased numbers of adverse events, including herpes zoster infections and creatinine and lipid elevations. Evidence Rating Level: 1 (Excellent) Study Rundown: This randomized, controlled study was designed to compare...
Image: PD  1. Patients with rheumatoid arthritis (RA) taking tofacitinib in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs) demonstrated an improvement in disease activity when compared to placebo.   Evidence Rating Level: 1 (Excellent)        Study Rundown:  Many patients with RA do not have adequate improvement in their disease activity despite...